Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2015

01.12.2015 | Hepatobiliary Tumors

Repeat Hepatectomy for Breast Cancer Liver Metastases

verfasst von: Aldrick Ruiz, MD, Carlos Castro-Benitez, MD, Mylène Sebagh, MD, Sylvie Giacchetti, MD, Edward Castro-Santa, MD, PhD, Dennis A. Wicherts, MD, PhD, Richard van Hillegersberg, MD, PhD, Bernard Paule, MD, Denis Castaing, MD, Jean-François Morère, MD, René Adam, MD, PhD

Erschienen in: Annals of Surgical Oncology | Sonderheft 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Resection of breast cancer liver metastases (BCLM) combined with systemic treatment is increasingly accepted as a therapeutic option; however, the potential benefit of repeat hepatectomy for recurrent BCLM is unknown.

Methods

All consecutive female patients who underwent liver resection for BCLM at our center between January 1985 and December 2012 were included. Patients who had a single hepatectomy (N = 120) were compared with those who also underwent repeat hepatectomy (N = 19). Patients were selected for repeat hepatectomy based on operability and disease control. Prognostic factors of survival after repeat hepatectomy were determined.

Results

Median overall survival since first hepatectomy was 35 months, with a 3- and 5-year survival rate of 50 and 38 %, respectively. Overall survival following repeat hepatectomy was 64 and 46 % at 3 and 5 years, respectively. From the time of first hepatectomy, patients who underwent repeat hepatectomy had a better survival than those who had only one hepatectomy (95 and 84 vs. 50 and 38 % at 3 and 5 years, respectively) (p = 0.002). Median survival was 35 and 100 months, respectively, and median survival since the diagnosis of BCLM was 51 and 112 months in the single and repeat hepatectomy groups, respectively. Since the time of diagnosis, overall 3-, 5-, and 7-year survival rates were 75, 57, and 44 %, respectively, for all 139 patients. Improved overall survival after repeat hepatectomy was related to a time interval between breast cancer diagnosis and first hepatectomy of >2 years, a limited hepatectomy, solitary liver metastasis, positive progesterone receptor status, and chemotherapy following repeat hepatectomy. Patients with single BCLM at first hepatectomy had a 3- and 5-year overall survival rate of 76 and 76 % compared with 51 and 17 % in patients with multiple metastases (p = 0.023).

Conclusion

In selected patients with BCLM, repeat hepatectomy for liver recurrence combined with systemic treatment provided survival rates comparable to those after first hepatectomy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
2.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRef Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRef
3.
Zurück zum Zitat Miller KD, Sledge GW Jr. The role of chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 1999;13(2):415–34.PubMedCrossRef Miller KD, Sledge GW Jr. The role of chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 1999;13(2):415–34.PubMedCrossRef
4.
Zurück zum Zitat Schuetz F, Diel IJ, Pueschel M, et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol. 2007;196(4):342.e1–9.CrossRef Schuetz F, Diel IJ, Pueschel M, et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol. 2007;196(4):342.e1–9.CrossRef
5.
Zurück zum Zitat Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–7.PubMedCrossRef Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–7.PubMedCrossRef
6.
Zurück zum Zitat Pogoda K, Niwinska A, Murawska M, et al. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30(1):388.PubMedPubMedCentralCrossRef Pogoda K, Niwinska A, Murawska M, et al. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30(1):388.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Berman AT, Thukral AD, Hwang WT, et al. Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clin Breast Cancer. 2013;13(2):88–94.PubMedCrossRef Berman AT, Thukral AD, Hwang WT, et al. Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clin Breast Cancer. 2013;13(2):88–94.PubMedCrossRef
8.
Zurück zum Zitat Follana P, Barriere J, Chamorey E, et al. Prognostic factors in 401 elderly women with metastatic breast cancer. Oncology. 2014;86(3):143–51.PubMedCrossRef Follana P, Barriere J, Chamorey E, et al. Prognostic factors in 401 elderly women with metastatic breast cancer. Oncology. 2014;86(3):143–51.PubMedCrossRef
9.
Zurück zum Zitat Sugihara K, Uetake H. Therapeutic strategies for hepatic metastasis of colorectal cancer: overview. J Hepatobiliary Pancreat Sci. 2012;19(5):523–7.PubMedCrossRef Sugihara K, Uetake H. Therapeutic strategies for hepatic metastasis of colorectal cancer: overview. J Hepatobiliary Pancreat Sci. 2012;19(5):523–7.PubMedCrossRef
10.
Zurück zum Zitat Fedorowicz Z, Lodge M, Al-asfoor A, et al. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. New York: Wiley; 2008.CrossRef Fedorowicz Z, Lodge M, Al-asfoor A, et al. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. New York: Wiley; 2008.CrossRef
11.
Zurück zum Zitat Chua TC, Saxena A, Liauw W, et al. Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer. 2011;47(15):2282–90.PubMedCrossRef Chua TC, Saxena A, Liauw W, et al. Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer. 2011;47(15):2282–90.PubMedCrossRef
12.
Zurück zum Zitat Wicherts DA, de Haas RJ, Salloum C, et al. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg. 2013;100(6):808–18.PubMedCrossRef Wicherts DA, de Haas RJ, Salloum C, et al. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg. 2013;100(6):808–18.PubMedCrossRef
13.
Zurück zum Zitat Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244(6):897–907. discussion 907–8.PubMedPubMedCentralCrossRef Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244(6):897–907. discussion 907–8.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Caralt M, Bilbao I, Cortes J, et al. Hepatic resection for liver metastases as part of the “oncosurgical” treatment of metastatic breast cancer. Ann Surg Oncol. 2008;15(10):2804–10.PubMedCrossRef Caralt M, Bilbao I, Cortes J, et al. Hepatic resection for liver metastases as part of the “oncosurgical” treatment of metastatic breast cancer. Ann Surg Oncol. 2008;15(10):2804–10.PubMedCrossRef
15.
Zurück zum Zitat Kollmar O, Moussavian MR, Richter S, et al. Surgery of liver metastasis in gynecological cancer: indication and results. Onkologie. 2008;31(7):375–9.PubMedCrossRef Kollmar O, Moussavian MR, Richter S, et al. Surgery of liver metastasis in gynecological cancer: indication and results. Onkologie. 2008;31(7):375–9.PubMedCrossRef
16.
Zurück zum Zitat Lubrano J, Roman H, Tarrab S, et al. Liver resection for breast cancer metastasis: does it improve survival? Surg Today. 2008;38(4):293–9.PubMedCrossRef Lubrano J, Roman H, Tarrab S, et al. Liver resection for breast cancer metastasis: does it improve survival? Surg Today. 2008;38(4):293–9.PubMedCrossRef
17.
Zurück zum Zitat Thelen A, Benckert C, Jonas S, et al. Liver resection for metastases from breast cancer. J Surg Oncol. 2008;97(1):25–9.PubMedCrossRef Thelen A, Benckert C, Jonas S, et al. Liver resection for metastases from breast cancer. J Surg Oncol. 2008;97(1):25–9.PubMedCrossRef
18.
Zurück zum Zitat Hoffmann K, Franz C, Hinz U, et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol. 2010;17(6):1546–54.PubMedCrossRef Hoffmann K, Franz C, Hinz U, et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol. 2010;17(6):1546–54.PubMedCrossRef
19.
Zurück zum Zitat Rubino A, Doci R, Foteuh JC, et al. Hepatic metastases from breast cancer. Updates Surg. 2010;62(3–4):143–8.PubMedCrossRef Rubino A, Doci R, Foteuh JC, et al. Hepatic metastases from breast cancer. Updates Surg. 2010;62(3–4):143–8.PubMedCrossRef
21.
Zurück zum Zitat Abbott DE, Brouquet A, Mittendorf EA, et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012;151(5):710–6.PubMedPubMedCentralCrossRef Abbott DE, Brouquet A, Mittendorf EA, et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012;151(5):710–6.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Duan XF, Dong NN, Zhang T, et al. Comparison of surgical outcomes in patients with colorectal liver metastases versus non-colorectal liver metastases: a Chinese experience. Hepatol Res. 2012;42(3):296–303.PubMedCrossRef Duan XF, Dong NN, Zhang T, et al. Comparison of surgical outcomes in patients with colorectal liver metastases versus non-colorectal liver metastases: a Chinese experience. Hepatol Res. 2012;42(3):296–303.PubMedCrossRef
23.
Zurück zum Zitat Groeschl RT, Nachmany I, Steel JL, et al. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis. J Am Coll Surg. 2012;214(5):769–77.PubMedCrossRef Groeschl RT, Nachmany I, Steel JL, et al. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis. J Am Coll Surg. 2012;214(5):769–77.PubMedCrossRef
24.
Zurück zum Zitat van Walsum GA, de Ridder JA, Verhoef C, et al. Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol. 2012;38(10):910–7.PubMedCrossRef van Walsum GA, de Ridder JA, Verhoef C, et al. Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol. 2012;38(10):910–7.PubMedCrossRef
25.
Zurück zum Zitat Dittmar Y, Altendorf-Hofmann A, Schule S, et al. Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature. J Cancer Res Clin Oncol. 2013;139(8):1317–25.PubMedCrossRef Dittmar Y, Altendorf-Hofmann A, Schule S, et al. Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature. J Cancer Res Clin Oncol. 2013;139(8):1317–25.PubMedCrossRef
26.
Zurück zum Zitat Kostov DV, Kobakov GL, Yankov DV. Prognostic factors related to surgical outcome of liver metastases of breast cancer. J Breast Cancer. 2013;16(2):184–92.PubMedPubMedCentralCrossRef Kostov DV, Kobakov GL, Yankov DV. Prognostic factors related to surgical outcome of liver metastases of breast cancer. J Breast Cancer. 2013;16(2):184–92.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Polistina F, Costantin G, Febbraro A, et al. Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg. 2013;37(6):1322–32.PubMedCrossRef Polistina F, Costantin G, Febbraro A, et al. Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg. 2013;37(6):1322–32.PubMedCrossRef
28.
Zurück zum Zitat Kim JY, Park JS, Lee SA, et al. Does liver resection provide long-term survival benefits for breast cancer patients with liver metastasis? A single hospital experience. Yonsei Med J. 2014;55(3):558–62.PubMedPubMedCentralCrossRef Kim JY, Park JS, Lee SA, et al. Does liver resection provide long-term survival benefits for breast cancer patients with liver metastasis? A single hospital experience. Yonsei Med J. 2014;55(3):558–62.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Weinrich M, Weiss C, Schuld J, et al. Liver resections of isolated liver metastasis in breast cancer: results and possible prognostic factors. HPB Surg. 2014;2014:893829.PubMedPubMedCentralCrossRef Weinrich M, Weiss C, Schuld J, et al. Liver resections of isolated liver metastasis in breast cancer: results and possible prognostic factors. HPB Surg. 2014;2014:893829.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Couinaud C. Variations of the right bile ducts. The futility of complete anatomical classifications [in French]. Chirurgie 1993;119(6–7):354–6.PubMed Couinaud C. Variations of the right bile ducts. The futility of complete anatomical classifications [in French]. Chirurgie 1993;119(6–7):354–6.PubMed
31.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.PubMedPubMedCentralCrossRef Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Abuzallouf S, Motawy M, Thotathil Z. Baseline staging of newly diagnosed breast cancer: Kuwait cancer control center experience. Med Princ Pract. 2007;16(1):22–4.PubMedCrossRef Abuzallouf S, Motawy M, Thotathil Z. Baseline staging of newly diagnosed breast cancer: Kuwait cancer control center experience. Med Princ Pract. 2007;16(1):22–4.PubMedCrossRef
33.
Zurück zum Zitat Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18(2):299–304.PubMedCrossRef Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18(2):299–304.PubMedCrossRef
34.
Zurück zum Zitat Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–51.PubMedCrossRef Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–51.PubMedCrossRef
Metadaten
Titel
Repeat Hepatectomy for Breast Cancer Liver Metastases
verfasst von
Aldrick Ruiz, MD
Carlos Castro-Benitez, MD
Mylène Sebagh, MD
Sylvie Giacchetti, MD
Edward Castro-Santa, MD, PhD
Dennis A. Wicherts, MD, PhD
Richard van Hillegersberg, MD, PhD
Bernard Paule, MD
Denis Castaing, MD
Jean-François Morère, MD
René Adam, MD, PhD
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe Sonderheft 3/2015
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4785-8

Weitere Artikel der Sonderheft 3/2015

Annals of Surgical Oncology 3/2015 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.